

Per Winkel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1735710/publications.pdf>

Version: 2024-02-01

64
papers

3,377
citations

257101

24
h-index

205818

48
g-index

69
all docs

69
docs citations

69
times ranked

6134
citing authors

#	ARTICLE	IF	CITATIONS
1	When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Medical Research Methodology, 2017, 17, 162.	1.4	1,400
2	Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Medicine, 2016, 42, 1695-1705.	3.9	292
3	Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial. BMJ, The, 2015, 350, g7635-g7635.	3.0	224
4	Neurologic Function and Health-Related Quality of Life in Patients Following Targeted Temperature Management at 33°C vs 36°C After Out-of-Hospital Cardiac Arrest. JAMA Neurology, 2015, 72, 634.	4.5	150
5	High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal, 2009, 30, 1066-1072.	1.0	148
6	Factors Contributing to Intra-Individual Variation of Serum Constituents: 2. Effects of Exercise and Diet on Variation of Serum Constituents in Healthy Subjects. Clinical Chemistry, 1973, 19, 1380-1383.	1.5	77
7	Factors Contributing to Intra-Individual Variation of Serum Constituents: 1. Within-Day Variation of Serum Constituents in Healthy Subjects. Clinical Chemistry, 1973, 19, 1374-1379.	1.5	72
8	Cardiac rehabilitation versus usual care for patients treated with catheter ablation for atrial fibrillation: Results of the randomized CopenHeartRFA trial. American Heart Journal, 2016, 181, 120-129.	1.2	70
9	Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. International Journal of Cardiology, 2015, 182, 459-465.	0.8	67
10	The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. Pediatric Research, 2016, 79, 528-535.	1.1	63
11	Effect of antenatal education in small classes versus standard auditorium-based lectures on use of pain relief during labour and of obstetric interventions: results from the randomised NEWBORN trial. BMJ Open, 2016, 6, e010761.	0.8	54
12	Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. European Stroke Journal, 2019, 4, 254-262.	2.7	48
13	Comprehensive cardiac rehabilitation improves outcome for patients with implantable cardioverter defibrillator. Findings from the COPE-ICD randomised clinical trial. European Journal of Cardiovascular Nursing, 2015, 14, 34-44.	0.4	43
14	Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry, the, 2017, 4, 605-618.	3.7	40
15	Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Intensive Care Medicine, 2016, 42, 1685-1694.	3.9	38
16	Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial. World Journal of Biological Psychiatry, 2016, 17, 514-524.	1.3	37
17	Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial. PLoS ONE, 2017, 12, e0173440.	1.1	37
18	Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial. Atherosclerosis, 2011, 214, 203-208.	0.4	34

#	ARTICLE	IF	CITATIONS
19	Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial. <i>American Heart Journal</i> , 2014, 168, 197-204.e4.	1.2	34
20	10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Association, 2018, 7, .	1.8	33
21	High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 52-62.	0.6	30
22	Feedback in group psychotherapy for eating disorders: A randomized clinical trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2017, 85, 484-494.	1.6	30
23	Low vs high hemoglobin trigger for transfusion in vascular surgery: a randomized clinical feasibility trial. <i>Blood</i> , 2019, 133, 2639-2650.	0.6	30
24	Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective. <i>Cardiology</i> , 2011, 118, 63-67.	0.6	27
25	Early physical training and psycho-educational intervention for patients undergoing coronary artery bypass grafting. The SheppHeart randomized 2 Å– 2 factorial clinical pilot trial. <i>European Journal of Cardiovascular Nursing</i> , 2016, 15, 425-437.	0.4	24
26	Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 121-126.	1.7	23
27	Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1275-1284.	0.8	22
28	Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study. <i>Atherosclerosis</i> , 2018, 278, 97-102.	0.4	22
29	Power estimations for non-primary outcomes in randomised clinical trials. <i>BMJ Open</i> , 2019, 9, e027092.	0.8	20
30	Prognosis and Reclassification by YKLâ€40 in Stable Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e014634.	1.6	20
31	Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 657-664.	0.6	18
32	Sexual rehabilitation for cardiac patients with erectile dysfunction: a randomised clinical trial. <i>Heart</i> , 2019, 105, 775-782.	1.2	16
33	Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 444-453.	2.4	15
34	Simple, lowâ€cost groupâ€counselling programme vs treatment as usual for patients with newly notified occupational hand eczemaâ€”Exploratory analyses of effects on knowledge, behaviour and personal resources of the randomized PREVEX clinical trial. <i>Contact Dermatitis</i> , 2018, 79, 127-135.	0.8	13
35	Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	1.0	12
36	Third-wave cognitive therapy versus mentalisation-based treatment for major depressive disorder: a randomised clinical trial. <i>BMJ Open</i> , 2014, 4, e004903-e004903.	0.8	11

#	ARTICLE	IF	CITATIONS
37	SheppHeartCABG trialâ€”comprehensive early rehabilitation after coronary artery bypass grafting: a protocol for a randomised clinical trial. <i>BMJ Open</i> , 2017, 7, e013038.	0.8	11
38	Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study. <i>Atherosclerosis</i> , 2019, 284, 202-208.	0.4	11
39	Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy. <i>Atherosclerosis</i> , 2020, 301, 8-14.	0.4	9
40	Statistical analysis plan for the EuroHYP-1 trial: European multicentre, randomised, phase III clinical trial of the therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke. <i>Trials</i> , 2017, 18, 573.	0.7	7
41	Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course. <i>Open Heart</i> , 2018, 5, e000808.	0.9	7
42	Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Upâ€”A CLARICOR Trial Sub-Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 265.	1.0	7
43	No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial. <i>Acta Neuropsychiatrica</i> , 2016, 28, 101-109.	1.0	6
44	Internet-based self-help therapy with FearFighterâ„¢ versus no intervention for anxiety disorders in adults: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 525.	0.7	6
45	The Clinical Significance of Classifications of Cirrhosis. A Comparison between Conventional Criteria and Numerical Taxonomy. <i>Scandinavian Journal of Gastroenterology</i> , 1976, 11, 33-40.	0.6	5
46	Effect of escitalopram versus placebo on GRÎ± messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression â€” a secondary outcome analysis from the randomized AGENDA trial. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 297-302.	0.7	4
47	Multivariate analysis and expert systems. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1994, 54, 12-24.	0.6	3
48	Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial. <i>BMJ Open</i> , 2020, 10, e033720.	0.8	2
49	Introductionâ€” on Quality of Health Care in General. , 0, , 1-7.		2
50	Control Charts for Autocorrelated Data. , 0, , 92-109.		1
51	Risk-Adjusted Control Charts. , 0, , 149-163.		1
52	Shewhart Control Charts. , 0, , 37-77.		0
53	Internet-based therapy with FearFighter for anxiety disorders: a randomised clinical trial. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 518-524.	0.7	0
54	A screening method to spot biomarkers that may warn of serious events in a chronic diseaseâ€” illustrated by cardiological CLARICOR trial data. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1852-1860.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Appendix Aâ€œ Basic Statistical Concepts. , 0, , 216-250.		0
56	Appendix Bâ€œ X and S Chart with Variable Sample Size. , 0, , 251-253.		0
57	Appendix Câ€œ Moving Range Estimator of the Standard Deviation of an AR (1) Process. , 0, , 254-255.		0
58	Theory of Statistical Process Control. , 0, , 9-36.		0
59	Time-Weighted Control Charts. , 0, , 78-91.		0
60	Tools for Risk Adjustment. , 0, , 111-148.		0
61	Risk-Adjusted Comparison of Healthcare Providers. , 0, , 164-181.		0
62	Learning Curves. , 0, , 183-194.		0
63	Assessing the Quality of Clinical Processes. , 0, , 195-215.		0
64	Statistics in Practice. , 0, , 264-264.		0